PDE4B

Palisade Bio Provides Corporate Update and Reiterates Guidance

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Ulcerative colitis, Receipt, Completeness, MHP, Exercise, Internet, Doctor of Pharmacy, PDE4B, UC, Inflammatory bowel disease, Patient, IBD, Initiate, Trial of the century, Pharmaceutical industry

Carlsbad, CA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today provided a corporate update and reiterated upcoming milestones.

Key Points: 
  • “We continue to make significant development progress with PALI-2108, our lead program.
  • The program is providing us with a growing body of data that we find encouraging, including support for a precision medicine approach,” commented J.D.
  • Although smaller, we believe the reconstituted board better matches our stage of development while retaining ethnic and gender diversity.
  • PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4B (PDE4B) inhibitor prodrug in development for patients affected by UC.

Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress

Retrieved on: 
Monday, January 29, 2024
Patient, Research, DSS, UC, Inflammatory bowel disease, DAI, Poster, PDE4, IBD, Dog, PDE4B, Plasma, AUC, Ulcerative colitis, Toxicity, Efficacy, Therapy, Vomiting, Absorption, Asian literature, Trial of the century, CNS, Pharmaceutical industry

Carlsbad, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced the presentation of positive preclinical data of its lead asset, PALI-2108 at the Crohn’s & Colitis Congress, which was held on January 25-27, 2024 in Las Vegas, NV.

Key Points: 
  • The preclinical data was presented in a poster titled, Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment.
  • PALI-2108 is the Company’s orally administered, locally acting colon-specific phosphodiesterase-4B (PDE4B) inhibitor prodrug in development for patients affected by moderate-to-severely active ulcerative colitis (UC).
  • The poster is available on the Scientific Publications page of the Company’s website .
  • This feature ensures localized bioactivation, leading to colon-specific distribution with limited systemic exposure, as confirmed by a tissue distribution study.

Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108

Retrieved on: 
Thursday, December 28, 2023
IBD, PDE4B, Patient, Inflammatory bowel disease, Therapy, UC, Pharmaceutical industry

Carlsbad, CA, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced the receipt of the second milestone payment to Giiant from the US Crohn’s and Colitis Foundation, through its Inflammatory Bowel Disease (IBD) Ventures program.

Key Points: 
  • Carlsbad, CA, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced the receipt of the second milestone payment to Giiant from the US Crohn’s and Colitis Foundation, through its Inflammatory Bowel Disease (IBD) Ventures program.
  • “We are grateful for the continued support of the Foundation and remain steadfast in our commitment to advance the treatment landscape for IBD.
  • We are encouraged by the potential of PALI-2108 and view this milestone payment from the US Crohn’s and Colitis Foundation as further validation of our precision approach for IBD treatment.
  • Our team continues to drive the clinical development of PALI-2108 toward the launch of a Phase 1 clinical study, which is on track for next year,” commented J.D.

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Retrieved on: 
Tuesday, August 1, 2023
Professional Services, Health, Finance, Pharmaceutical, Biotechnology, Veterinary, Livestock, Idiopathic disease, Research and development, Idiopathic pulmonary fibrosis, Heart failure, Chronic kidney disease, Diabetes, Myocardial infarction, Executive officer, Flea, Cancer, BI, Retina, Animal Health, Coccidioides immitis, Tick, Boehringer Ingelheim, Development, EUR, Patient, Investment, PDE4B, Dog, Cat, IPF, FDA, Disease, Fine chemical, Pharmaceutical industry, Pet

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health expanding across its key therapy areas.

Key Points: 
  • Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health expanding across its key therapy areas.
  • Overall, the company has committed to invest 25 billion EUR in Research & Development and an additional 7 billion EUR for new production technologies over the next five years.
  • Jardiance® experienced strong momentum in the first six months of 2023.
  • With the addition to existing indications in type 2 diabetes and heart failure, Jardiance® will potentially be able to help manage cardio-renal-metabolic conditions.

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

Retrieved on: 
Tuesday, May 9, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Tissue, Graft-versus-host disease, Heart, SingHealth, Partnership, Boehringer, Doctor of Philosophy, Neoplasm, Infection, Survival, Pharmacokinetics, Quality of life, Scar, PDE4B, Inflammation, DSM-IV codes, Lung, Pulmonary fibrosis, Boehringer Ingelheim, Duke–NUS Medical School, Fibrosis, Death, Discovery, Patient, Vicki Belo, Circulatory system, Biology, Liver, IPF, Safety, Pharmaceutical industry

Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas.

Key Points: 
  • Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas.
  • The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte.
  • ‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues.
  • Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis.

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Retrieved on: 
Sunday, May 15, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pulmonary fibrosis, Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, International Conference on Afghanistan, London (2010), Patient, Principal investigator, Vital capacity, Phase, NEJM, American Thoracic Society, Diarrhea, The New England Journal of Medicine, PDE4B, Hope, Respiratory Medicine, FDA, Probability, Conference, ATS, PPF, Atmosphere, Board, Safety, Executive Office of the President of the United States, Boehringer Ingelheim, Idiopathic pulmonary fibrosis, IPF, FVC, Pharmaceutical industry, Medical device

In patients already taking antifibrotic therapy, the median changes in FVC were +2.7 mL for BI 1015550 and -59.2 mL in the placebo arm.

Key Points: 
  • In patients already taking antifibrotic therapy, the median changes in FVC were +2.7 mL for BI 1015550 and -59.2 mL in the placebo arm.
  • There is >98% probability that BI 1015550 was superior to placebo in slowing down the worsening of lung function in people with IPF.
  • The Phase II results reinforce our confidence in BI 1015550 which will be accelerated into a pivotal Phase III program.
  • We will work with regulatory agencies and scientific communities to potentially bring the next generation of treatments to people living with pulmonary fibrosis as quickly as possible.

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Pharmaceutical, Health, Clinical trials, Molecular biology, Phosphodiesterase, Phosphodiester bond, PDE1, PDE4B, Benjamin Weiss

The "Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Type 4 cyclic nucleotide phosphodiesterase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Type 4 cyclic nucleotide phosphodiesterase inhibitors pipeline landscape.
  • Type 4 cyclic nucleotide phosphodiesterase inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Type 4 cyclic nucleotide phosphodiesterase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Type 4 cyclic nucleotide phosphodiesterase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.